Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologySierra Health and Life Omvoh Coverage Update | Ope…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0129F

    Omvoh (mirikizumab-mrkz) coverage for UC and CD

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0129F alerts

    Get alerted when Policy 2026D0129F changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical and pharmacy benefit coverage and prior authorization requirements for Omvoh (mirikizumab-mrkz) for treatment of moderately to severely active ulcerative colitis and Crohn's disease for UnitedHealthcare Commercial and Individual Exchange plans.

    Policy Summary
    Payersierra health and life
    PolicyOmvoh (mirikizumab-mrkz) coverage for UC and CD
    Policy CodePolicy 2026D0129F
    Change TypeRevised combination therapy restrictionupdated exemplar agent lists
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionObtain prior authorization for three intravenous induction doses and confirm the patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for the same indication.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Revised coverage criteria to clarify combination therapy restriction to 'the patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication'.

    Updated lists of example systemic targeted immunomodulators that must not be used in combination with Omvoh for UC and CD and updated lists of prior targeted agents.

    Application section added to indicate policy applies to UnitedHealthcare Commercial and Individual Exchange benefit plans.

    3induction IV doses authorized
    J2267HCPCS code listed
    65% / 24%UC-1 Week 12 response/remission
    1062subjects in UC-1 induction study
    71%UC-1 % White

    Coverage Criteria for Omvoh (mirikizumab-mrkz)

    Ulcerative Colitis — Induction

    Covered when ALL of the following are met:

    UC Induction - all required: Diagnosis of moderately to severely active ulcerative colitis; and Omvoh to be administered as three intravenous induction doses; and Omvoh induction dosing is in accordance with the United States Food and Drug Administration (FDA) labeled dosing for UC; and patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication; and authorization will be issued for 3 induction doses

    Applies to Commercial and Individual Exchange plans unless benefit documents specify otherwise

    Crohn's Disease — Induction

    Covered when ALL of the following are met:

    CD Induction - all required: Diagnosis of moderately to severely active Crohn's disease; and Omvoh to be administered as three intravenous induction doses; and Omvoh induction dosing is in accordance with the United States Food and Drug Administration (FDA) labeled dosing for CD; and patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication; and prescribed by or in consultation with a gastroenterologist; and authorization will be issued for 3 induction doses

    For Community Plan, also require prior inadequate response to conventional therapies or prior targeted immunomodulator per Community Plan text

    Community Plan — Prior therapy requirement

    For the Community Plan, coverage requires either:

    Community Plan prior therapy: Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine); OR patient has been previously treated with a systemic targeted immunomodulator FDA-approved for the treatment of the indication (examples provided in Community Plan policy).

    Applies to Ulcerative Colitis and Crohn's Disease under Community Plan policy text

    Initial and maintenance therapy coverage criteria

    Covered when ALL of the following are met (reflecting trial populations and revised policy language):

    Indication and severity: Adult patient with moderately to severely active ulcerative colitis or Crohn's disease as defined by trial entry criteria (UC: modified Mayo score [mMS] 5–9 with centrally read endoscopy subscore 2–3; CD: CDAI ≥ 220 and SES-CD thresholds per study).see trial definitions

    Based on UC-1/UC-2 and CD-1 trial entry definitions

    Prior therapy history: Patient has inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, and/or biologic therapy or JAK inhibitor as applicable, consistent with populations studied.document prior agents and outcomes

    Refer to UC-1/UC-2 and CD-1 for studied populations

    Concomitant therapy: If on concomitant aminosalicylates or immunomodulators, doses must be stable; corticosteroid tapering required for patients who were receiving corticosteroids at baseline and achieved response in induction per study design.

    Use of Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication is not allowed. This restriction applies to concurrent systemic targeted immunomodulators administered for the same disease (ulcerative colitis or Crohn's disease) and is a condition of medical necessity and authorization for Omvoh.

    Examples of systemic targeted immunomodulators with which Omvoh must not be combined are listed in the policy text and include, for ulcerative colitis and Crohn's disease, agents such as adalimumab, vedolizumab (Entyvio), upadacitinib (Rinvoq), risankizumab (Skyrizi), guselkumab (Tremfya), tofacitinib (Xeljanz/Xeljanz XR), ustekinumab, and others as enumerated in the coverage criteria. The policy history documents that example lists were revised on 05/01/2026, with additions (e.g., vedolizumab, guselkumab, ozanimod) and removals or replacements of other named agents; prior targeted agents relevant to prior‑therapy determinations were likewise updated.

    FDA approval of Omvoh is informational only and does not by itself establish coverage. Coverage is determined through a separate medical necessity review consistent with the applicable UnitedHealthcare plan; the policy states that FDA approval alone is not a basis for coverage and that a plan‑specific medical necessity determination is required.

    Coding and Diagnostic Codes

    Applicable HCPCS CodesHCPCS
    J2267Injection, mirikizumab-mrkz, 1 mg.
    Applicable ICD-10 Diagnosis Codes (UC and CD)ICD-10
    K50.011Crohn's disease of small intestine with rectal bleeding.
    K50.012Crohn's disease of small intestine with intestinal obstruction.
    K50.013Crohn's disease of small intestine with fistula.
    K50.014Crohn's disease of small intestine with abscess.
    K50.018Crohn's disease of small intestine with other complication.
    K50.019Crohn's disease of small intestine with unspecified complications.
    K50.10Crohn's disease of large intestine without complications.
    K50.111Crohn's disease of large intestine with rectal bleeding.
    K50.112Crohn's disease of large intestine with intestinal obstruction.
    K50.113Crohn's disease of large intestine with fistula.
    1–10 of 37
    1/4
    Codes mentionedmixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes listed in this document excerpt.
    modified Mayo score (mMS) — baseline/definition and severity thresholds
    Score range0–9 (sum of three subscores: stool frequency, rectal bleeding, centrally read endoscopy), each subscore 0–3
    Baseline trial range (UC-1)mMS 5 to 9 (median 7)
    Severe disease thresholdSevere disease defined as mMS 7 to 9 (58% of UC-1 subjects)
    Endoscopy subscore requirementCentrally read endoscopy subscore of 2 or 3 at baseline
    Disease activity scores — mMS for UC; CDAI and SES‑CD for CD thresholds used in trials
    UC disease activity (mMS)mMS 5–9 with centrally read endoscopy subscore 2–3 used to define moderately to severely active UC in trials

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior authorization for 3 induction doses

    Prior authorization is required for Omvoh; when criteria are met authorization will be issued for three induction doses administered as IV infusions consistent with FDA‑labeled dosing.

    • HCPCS code listed: J2267 (see coding) — use for prior auth submission as appropriate
    Prior Authorization

    Confirm coverage criteria and combination‑therapy restriction

    Confirm the patient meets all coverage criteria before requesting authorization, including diagnosis of moderately to severely active UC or CD, required prior treatment history (when applicable), and that Omvoh will not be administered in combination with another systemic targeted immunomodulator for the same indication.

    • Authorization must verify absence of concurrent systemic targeted immunomodulator for the same indication (policy lists examples).
    • Prescriber should be a gastroenterologist or consult one as required by the criteria.

    Background and Definitions

    Omvoh (mirikizumab‑mrkz) is a humanized IgG4 monoclonal antibody that selectively binds the p19 subunit of interleukin‑23 (IL‑23), inhibiting IL‑23 interaction with its receptor and downstream mucosal inflammatory pathways. Clinical development included randomized controlled trials in ulcerative colitis (UC‑1 and UC‑2) and Crohn's disease (CD‑1) evaluating intravenous induction and maintenance dosing; UC induction trials enrolled patients with baseline modified Mayo scores typically in the 5–9 range, and CD trials used CDAI and SES‑CD thresholds for entry. Authorization in the policy is aligned to the studied IV induction regimen (three induction doses) and to the indication for moderately to severely active UC and CD.

    Omvoh (mirikizumab-mrkz) — Key drug definition
    Generic and brandOmvoh (mirikizumab-mrkz)
    Molecule classHumanized IgG4 monoclonal antibody
    TargetBinds the p19 subunit of interleukin‑23 (IL‑23), inhibiting interaction with the IL‑23 receptor
    Indication contextDeveloped for treatment of moderately to severely active ulcerative colitis and Crohn's disease in clinical trials
    Policy Summary
    Payersierra health and life
    PolicyOmvoh (mirikizumab-mrkz) coverage for UC and CD
    Policy CodePolicy 2026D0129F
    Change TypeRevised combination therapy restrictionupdated exemplar agent lists
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionObtain prior authorization for three intravenous induction doses and confirm the patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for the same indication.
    SourceLink
    On This Page
    Coverage Criteria for Omvoh (mirikizumab-mrkz)Coding and Diagnostic CodesProvider Actions, Authorization, and DocumentationBackground and Definitions
    document stable dosing and taper plan

    Reflects UC-1/UC-2 trial requirements

    Combination therapy restriction: Patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication.confirm no concurrent systemic targeted immunomodulator for same indication

    Revised coverage criterion; examples of systemic targeted immunomodulators added/removed in policy history

    CD clinical activity (CDAI)CDAI ≥ 220 used to define moderately to severely active Crohn's disease in CD-1
    CD endoscopic activity (SES-CD)SES‑CD ≥ 7 for ileal‑colonic disease or ≥ 4 for isolated ileal disease in CD-1
    Trial contextScores were assessed at baseline in UC-1 and CD-1 to define study populations and eligibility
    Step Therapy

    Document prior inadequate response or prior targeted therapy (Community Plan & CD)

    For Community Plan members and for Crohn’s disease under the general criteria, document prior inadequate response to conventional therapies (corticosteroids, 6‑mercaptopurine, azathioprine, or methotrexate) OR prior treatment with an FDA‑approved systemic targeted immunomodulator for the indication.

    • Conventional therapies include prednisone, methylprednisolone, budesonide, 6‑mercaptopurine, azathioprine, and methotrexate.
    • Prior targeted agents examples are listed in the policy (e.g., adalimumab, vedolizumab, upadacitinib, ustekinumab, others).
    Step Therapy

    Prior treatment history expected (informational)

    Policy expectations (informational): prior inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, and/or biologic therapy or JAK inhibitors were part of the studied populations and are referenced as prior treatment requirements for authorization.

    • UC trials allowed stable aminosalicylates, immunomodulators, and corticosteroids with defined tapering; CD trial populations included patients with prior loss of response/inadequate response to biologics.
    • Document prior agents tried and outcomes (failure, intolerance, or loss of response).
    Documentation Required

    Required prescriber clinical documentation

    Include prescriber documentation of the diagnosis, statement that Omvoh will be administered as three IV induction doses per FDA labeling, and whether the patient has previously received targeted immunomodulators (or other prior therapies as applicable).

    • If Community Plan, indicate prior or concurrent inadequate response to corticosteroids/immunosuppressants or prior targeted immunomodulator exposure as specified.
    • Indicate prescriber specialty or consultation (prescribed by or in consultation with a gastroenterologist where required).
    Documentation Required

    Clinical documentation to support medical necessity

    Support medical necessity with baseline disease activity and prior treatment history: for UC include modified Mayo score (mMS) and endoscopy subscore (baseline mMS 5–9 with endoscopy subscore 2–3); for CD include CDAI and SES‑CD (CDAI ≥220 and SES‑CD thresholds) and documentation of prior biologic/JAKi exposure and concomitant therapies/steroid taper plan as applicable.

    • Document baseline mMS, CDAI, and SES‑CD values where available.
    • Document prior biologic or JAK inhibitor exposure, outcomes, and any concomitant UC/CD therapies with stability or taper plans.
    Denial Risk

    Denial risk: combination therapy or non‑authorized induction dosing

    Requests may be denied if Omvoh is prescribed concurrently with another systemic targeted immunomodulator for the same indication or if induction dosing exceeds the authorized three IV induction doses consistent with FDA‑labeled dosing.

    • Policy lists example systemic targeted immunomodulators that must not be used in combination with Omvoh; updated examples are in the policy history.
    • Authorization is issued for three induction IV doses — exceeding this induction regimen may lead to denial.
    Denial Risk

    Combination therapy restriction — verify no concurrent systemic targeted immunomodulator

    Use of Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication may trigger denial under the revised coverage criterion; verify no concurrent systemic targeted immunomodulator for the same indication before approval.

    • Policy revision clarifies the prohibition applies to 'systemic targeted immunomodulator for treatment of the same indication' and updates example agent lists.
    • Ensure prior authorization documentation confirms compliance with this restriction.
    modified Mayo score (mMS) — Definition as a UC disease activity score (0–9)
    PurposeUC disease activity score used to assess severity and trial eligibility
    Score rangeTotal 0–9 composed of three subscores each 0–3 (stool frequency, rectal bleeding, centrally read endoscopy)
    Baseline trial valuesBaseline mMS in UC-1 was 5–9 with a median of 7; 58% had mMS 7–9 (severe)
    Endoscopy definitionsEndoscopy subscore 2 = marked erythema, absent vascular pattern, friability, erosions; subscore 3 = spontaneous bleeding and ulceration
    Modified Mayo score (mMS) — Trial baseline values and components
    Induction dosing contextmMS assessed at baseline in UC-1 where subjects received IV mirikizumab at Weeks 0, 4, and 8
    Baseline numeric valuesSubjects had mMS of 5 to 9 (median 7) with endoscopy subscore 2 or 3
    Subscore componentsThree subscores: stool frequency, rectal bleeding, findings on centrally read endoscopy (each 0–3)
    Severity distribution58% of UC-1 subjects had severely active disease (mMS 7–9)
    CDAI and SES-CD — Crohn's disease activity measure definitions and thresholds
    CDAI thresholdCDAI ≥ 220 used to define moderately to severely active Crohn's disease in CD‑1
    SES‑CD thresholdsSES‑CD ≥ 7 (centrally read) for ileal‑colonic disease; SES‑CD ≥ 4 for isolated ileal disease
    Baseline medians in CD‑1Median CDAI 329 and median SES‑CD 12 at baseline
    Assessment methodsDisease activity assessed by CDAI and SES‑CD for eligibility and endpoints in CD‑1